Overview
- SITraN and Aclipse Therapeutics reported peer‑reviewed preclinical results in Molecular Neurodegeneration on the candidate drug M102.
- Mouse studies showed improved movement and gait with preserved nerve and muscle function compared with controls.
- Lab experiments found the compound protected motor neurones grown from patient cells against disease‑related damage.
- Researchers say the data justify moving toward first‑in‑human testing, with regulatory and funding steps still required.
- Motor neurone disease has few treatment options and typically short survival, with about 5,000 people affected in the UK.